1-20 of 78
axicabtagene ciloleucel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Clinical Trials & Observations Brief Report
Vicki Plaks, John M. Rossi, Justin Chou, Linghua Wang, Soumya Poddar, Guangchun Han, Zixing Wang, Shao-Qing Kuang, Fuliang Chu, Richard E. Davis, Francisco Vega, Zahid Bashir, Caron A. Jacobson, Frederick L. Locke, Patrick M. Reagan, Scott J. Rodig, Lazaros J. Lekakis, Ian W. Flinn, David B. Miklos, Adrian Bot, Sattva S. Neelapu
Journal: Blood
Blood (2021) 138 (12): 1081–1085.
DOI: https://doi.org/10.1182/blood.2021010930
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

Clinical Trials & Observations
Jay Y. Spiegel, Saurabh Dahiya, Michael D. Jain, John Tamaresis, Loretta J. Nastoupil, Miriam T. Jacobs, Armin Ghobadi, Yi Lin, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Andre Goy, Khoan Vu, Charalambos Andreadis, Javier Munoz, N. Nora Bennani, Julie M. Vose, Kathleen A. Dorritie, Sattva S. Neelapu, Frederick L. Locke, Aaron P. Rapoport, Brian T. Hill, David B. Miklos
Journal: Blood
Blood (2021) 137 (13): 1832–1835.
DOI: https://doi.org/10.1182/blood.2020006245
Published: 2021
Includes: Supplemental data
Journal Articles

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Caron A. Jacobson, Olalekan O. Oluwole, Javier Munoz, Abhinav Deol, David B. Miklos, Nancy L. Bartlett, Ira Braunschweig, Yizhou Jiang, Jenny J. Kim, Lianqing Zheng, John M. Rossi, Frederick L. Locke
Journal: Blood
Blood (2020) 135 (23): 2106–2109.
DOI: https://doi.org/10.1182/blood.2019004162
Published: 2020
Includes: Supplemental data
Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4719.
DOI: https://doi.org/10.1182/blood-2019-122587
Published: 2019
Journal Articles

Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium

Miriam T. Jacobs, MD, Michael D. Jain, MD PhD, Jay Y. Spiegel, MDFRCPC, Loretta J. Nastoupil, MD MSc, Yibo Li, MD, Gao Feng, Matthew A. Lunning, DO, FACP, Lazaros J Lekakis, MD, Saurabh Dahiya, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Charalambos Andreadis, MD MSCE, Javier Munoz, MD, Julio Chavez, N. Nora Bennani, MD, Aaron P. Rapoport, Julie M Vose, MDMBA, David B Miklos, MD PhD, Sattva S Neelapu, MD, Armin Ghobadi, MD, Frederick L. Locke, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1583.
DOI: https://doi.org/10.1182/blood-2019-131168
Published: 2019
Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1599.
DOI: https://doi.org/10.1182/blood-2019-127490
Published: 2019
Journal Articles

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Richard J Lin, MD PhD, Stephanie M Lobaugh, MS, Martina Pennisi, Jason T Chan, RN, Yakup Batlevi, PhD, Josel D Ruiz, MPH, Theresa A Elko, MS, Molly A. Maloy, MS, Connie Lee Batlevi, MD PhD, Parastoo B. Dahi, MD, Sergio A Giralt, MD, Elena Mead, MD, Ariela Noy, MD, Maria Lia Palomba, MD, Bianca Santomasso, MD PhD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MD, Beatriz Korc-Grodzicki, MD PhD, Soo Jung Kim, NP, Mari Lynne Silverberg, Chelsea A Brooklyn, Sean M. Devlin, PhD, Miguel-Angel Perales, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1603.
DOI: https://doi.org/10.1182/blood-2019-125162
Published: 2019
Journal Articles

Resistance to Axicabtagene Ciloleucel Therapy in T Cell/Histiocyte-Rich Large B Cell Lymphoma

Jonathan Trujillo, MD PhD, James Godfrey, MD, Michael R. Bishop, MD, Peter A. Riedell, MD, Justin Kline, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5238.
DOI: https://doi.org/10.1182/blood-2019-131941
Published: 2019
Journal Articles

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Caspian Oliai, MD, Sven de Vos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5360.
DOI: https://doi.org/10.1182/blood-2019-129371
Published: 2019
Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy
Journal: Blood
Blood (2019) 134 (Supplement_1): 5308.
DOI: https://doi.org/10.1182/blood-2019-128812
Published: 2019
Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Megan Melody, MD, Sangeetha Gandhi, MBBS, Zaid Abdel Rahman, MD, Paula A Lengerke Diaz, MD, Nicole Gannon, PA-C, Allison C. Rosenthal, DO, Tuan Truong, Mattia Novo, Eva Brandes, Gina Lange, Breanna Estby, RN, Patrick Johnston, MD PhD, Stephen M Ansell, MD PhD, N. Nora Bennani, MD, Jonas Paludo, MD, Jose Villasboas, MD, Ernesto Ayala, MD, Han W. Tun, MD, Hemant S. Murthy, MD, Vivek Roy, MD, James M. Foran, MD, Januario E. Castro, MD, Yi Lin, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5343.
DOI: https://doi.org/10.1182/blood-2019-126594
Published: 2019
Journal Articles

Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR

Zaid Abdel Rahman, MD, Nicole Gannon, PA-C, Megan Melody, MD, Paul Muniz, RN, Ernesto Ayala, MD, Vivek Roy, MD, Lisa Brumble, Sikander Ailawadhi, MD, Taimur Sher, MD, James M. Foran, MD, Hemant S. Murthy, MD, Han W. Tun, MD, Candido E. Rivera, MD, Asher A. Chanan-Khan, MD, Abba C. Zubair, MD PhD, Mohamed A Kharfan-Dabaja, MDMBA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5610.
DOI: https://doi.org/10.1182/blood-2019-122067
Published: 2019
Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini
Journal: Blood
Blood (2019) 134 (Supplement_1): 5619.
DOI: https://doi.org/10.1182/blood-2019-125286
Published: 2019
Journal Articles

Real-World Data of High-Grade Lymphoma Patients Treated with CD19 CAR-T in England

Andrea Kuhnl, Claire Roddie, PhD MD, Nuria Martinez-Cibrian, Tobias F Menne, MD PhD FRCPath, Kim Linton, MBChB PhD, Sanne Lugthart, Sridhar Chaganti, MDPhDMRCP,FRCPath, Robin Sanderson, MRCP,FRCPath, Maria A V Marzolini, Jane Norman, MD, Wendy Osborne, MD, John Radford, Stephen Robinson, MBBS, PhD BSc, Ram Malladi, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Maeve A O'Reilly, MBBCHBAO, Muhammad Saif, MD, Geoff Shenton, Adrian Bloor, FRCPath, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, David A. Irvine, BSc, MBBChir, MRCP, FRCPath, PhD, Orla Stewart, Arzhang Ardavan, Kate Robinson, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Kristian M Bowles, MBBS, PhD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Rod Johnson, Andrew K McMillan, FRCP
Journal: Blood
Blood (2019) 134 (Supplement_1): 767.
DOI: https://doi.org/10.1182/blood-2019-124177
Published: 2019
Journal Articles

Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma

Matthew J. Frank, MD PhD, Nasheed Hossain, MD, Ali Bukhari, MD, Erin Dean, MD, Jay Y. Spiegel, MDFRCPC, Gursharan K. Claire, MPH, Ilan M. Kirsch, Allison P. Jacob, Chelsea D Mullins, BS, Lik Wee Lee, PhD, Katherine A. Kong, Juliana Craig, BA, Crystal L. Mackall, MD, Aaron P. Rapoport, Saurabh Dahiya, MD, Frederick L. Locke, MD, David B Miklos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 884.
DOI: https://doi.org/10.1182/blood-2019-132057
Published: 2019
Journal Articles

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel

Zinaida Good, PhD, Jay Y. Spiegel, MDFRCPC, Bita Sahaf, PhD, Meena B. Malipatlolla, Matthew J. Frank, MD PhD, John Baird, MD, Lori S Muffly, MD, Gursharan K. Claire, MPH, Juliana Craig, BA, Katherine A. Kong, Sean Bendall, PhD, David B Miklos, MD PhD, Crystal L. Mackall, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 779.
DOI: https://doi.org/10.1182/blood-2019-130815
Published: 2019
Journal Articles

Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis

Adam S. Kittai, MD, Max J. Gordon, MD, Agrima Mian, MBBS, MD, Lindsey Fitzgerald, MD, Jennifer Bishop, Deborah M. Stephens, DO, Sarah J. Nagle, MD, Brian T. Hill, MD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 780.
DOI: https://doi.org/10.1182/blood-2019-124694
Published: 2019
Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1612.
DOI: https://doi.org/10.1182/blood-2019-126148
Published: 2019
Journal Articles

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Martina Pennisi, Miriam Sanchez-Escamilla, MD, Jessica Flynn, BS, Molly A. Maloy, MS, Mari Lynne Silverberg, Yakup Batlevi, PhD, Roni Shouval, Connie Lee Batlevi, MD PhD, Renier J. Brentjens, MD PhD, Sean M. Devlin, PhD, Parastoo B. Dahi, MD, Claudia Diamonte, RN, Sergio A Giralt, MD, Elizabeth Halton, NP-BC AOCNP, Tania Jain, MD, Elena Mead, MD, Maria Lia Palomba, MD, Bianca Santomasso, MD PhD, Craig S. Sauter, MD, Michael Scordo, MD, Gunjan L. Shah, MD, Jae H. Park, MD, Miguel-Angel Perales, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1947.
DOI: https://doi.org/10.1182/blood-2019-126208
Published: 2019
Journal Articles

Real-World Analysis of Adverse Events Associated with CAR T-Cell Therapy Among Adults Age ≥65 Years

Marjorie E Zettler, PhD MPH, Bruce A Feinberg, DO, Eli G Phillips Jr., PharmD, JD, Andrew J Klink, PhD MPH, Sonam Mehta, Ajeet Gajra, MD FACP
Journal: Blood
Blood (2019) 134 (Supplement_1): 1951.
DOI: https://doi.org/10.1182/blood-2019-127372
Published: 2019